AMG-900 is a potent and selective inhibitor of Aurora kinases, particularly Aurora A and Aurora B, which play critical roles in cell cycle regulation, specifically during mitosis. Due to its ability to disrupt mitotic progression, AMG-900 has been investigated as an anticancer agent, especially in tumors with high rates of cell proliferation. It induces cell cycle arrest and promotes apoptosis in cancer cells, making it a candidate for treating resistant or aggressive cancers such as prostate, ovarian, and hematological malignancies. Its mechanism allows it to overcome resistance seen with other chemotherapeutics, including taxanes. AMG-900 has shown activity in preclinical models against tumor cells that overexpress Aurora kinases or have defects in cell cycle checkpoints. It is primarily used in research settings to study mitotic pathways and evaluate targeted cancer therapies.